Proposal by the Savoy Foundation for Epilepsy to Pharmaceutical Companies Manufacturing Anti-Epileptic Medications, Savoy G, Savoy C, St-Jean-sur-Richelieu, Quebec
---------------------------------------

Every year, only a few excellent requests by post-doctorate applicants for epilepsy research can be funded by the Savoy Foundation.  In order to increase the funds to benefit more applicants from all parts of the world in any of the Canadian centers, we propose to double the number of these fellowships annually by an equal contribution from pharmaceutical companies.

The Board of Administration of the Savoy Foundation for epilepsy, represented by George M Savoy, the president, and Caroline Savoy, the secretary-treasurer, and members of its medical board, wish to offer a financial contribution to match 50% of $35,000.00 post-doctoral annual bursaries offered in collaboration with pharmaceutical companies manufacturing anti-epileptic medications.  These include although not exclusively Abbot Ltd, Pfizer Canada Inc, Aventis Pharma Inc, Draxis Inc, Hoffman-LaRoche Ltd, Novartis Pharmaceuticals Canada Inc and Janssen-Ortho Inc, Lundbeck Canada Inc.  Candidate proposals could be evaluated by the Medical Board of the Savoy Foundation representing four Quebec universities and the Canadian League Against Epilepsy.

Corresponding Author:
Guy Marcel Remillad
10720, rue Tanguay
Hopital du Sacre-Coeur de Montreal
Montreal, Québec, Canada H3L 3H2
514-337-8310
514-337-7564
gremillard007@hotmail.com